STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News, Feb-Apr 2022

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Takeda announced its presentation of four abstracts at the 2022 Tandem Meetings and ECCMID, focusing on LIVTENCITY (maribavir) for post-transplant cytomegalovirus (CMV) infections. Key findings include a 34.8% reduction in hospitalizations and a 53.8% decrease in hospital stay duration for LIVTENCITY-treated patients compared to conventional therapies. Additionally, subgroup analyses indicate quicker CMV DNA level clearance with LIVTENCITY. These presentations support LIVTENCITY's role as a new treatment option for CMV infections resistant to conventional therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
none
-
Rhea-AI Summary

Takeda has received approval from the Japan Ministry of Health for its recombinant protein-based COVID-19 vaccine, Nuvaxovid, for individuals aged 18 and older. The approval covers both primary and booster immunization, based on positive efficacy and safety data from clinical trials conducted in Japan and internationally. Takeda will manufacture the vaccine at its Hikari facility and begin distribution shortly. The financial impact of Nuvaxovid on Takeda's fiscal year ending March 31, 2023, will depend on distribution schedules, with forecasts to be revealed in May 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
covid-19
-
Rhea-AI Summary

Takeda has launched the TAKHZYRO® (lanadelumab-flyo) injection in a single-dose prefilled syringe format in the U.S. to prevent hereditary angioedema (HAE) attacks in patients aged 12 and older. Approved by the FDA in February 2022, this user-friendly option aims to enhance patient experience by simplifying the administration process. TAKHZYRO has been available since 2018 and shows proven efficacy in preventing HAE attacks, supported by one of the largest clinical studies in the field. Patients and specialty pharmacies will receive guidance for the transition to this new format.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
Rhea-AI Summary

Takeda Pharmaceutical Company Limited has completed its share buyback program as outlined in the Board of Directors’ resolution from October 28, 2021. In April 2022, Takeda repurchased 6,907,500 shares of common stock at a total cost of JPY 24,992,962,200. This acquisition is part of a broader plan to buy back up to JPY 100 billion worth of shares (up to 35 million shares). The program aims to enhance shareholder value and optimize capital structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
-
Rhea-AI Summary

Takeda announced the completion of the SHP643-301 study, a Phase 3 trial evaluating TAKHZYRO (lanadelumab) for preventing acute attacks of hereditary angioedema (HAE) in pediatric patients aged 2 to 12 years. The study met its primary and secondary objectives, demonstrating a safety profile consistent with previous trials in older patients, with no serious adverse events reported. Takeda plans to initiate a global regulatory filing for this age group within the fiscal year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Rhea-AI Summary

Takeda proposes new candidates for independent external directors at its upcoming shareholders' meeting on June 29, 2022. The candidates, Kimberly A. Reed and John Maraganore, will replace retiring directors Toshiyuki Shiga and Shiro Kuniya. Additionally, Masami Iijima is nominated as the new chair of the Board Meetings, succeeding Masahiro Sakane. This move aims to enhance governance and diversity within the board. All current members will also be proposed for re-election.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
Rhea-AI Summary

Takeda has received approval from Japan's Ministry of Health, Labour and Welfare for TAKHZYRO (lanadelumab) subcutaneous injection in adults and pediatric patients aged 12 and older for preventing attacks of hereditary angioedema (HAE). This decision is primarily based on results from the global Phase 3 HELP Study and a Japan-specific Phase 3 trial, where 41.7% of patients did not experience attacks over 26 weeks. The drug is already approved in over 50 countries and aims to enhance treatment options for the HAE patient community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Summary

Takeda presented interim real-world data from the Phase 4 EMPOWER study, showing significant improvements in Hereditary Angioedema (HAE) treatment outcomes with TAKHZYRO (lanadelumab). New users experienced an average 83% reduction in monthly attack rates, while established users reported enhanced treatment satisfaction. Key metrics included improvements in the Angioedema Quality of Life Questionnaire and a notable percentage of users extending treatment intervals from every 2 weeks to 4 weeks. Full data is expected in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
Rhea-AI Summary

Takeda has announced promising six-month interim results from the INSPIRE study, which evaluated the effectiveness of Alofisel (darvadstrocel) in patients with complex Crohn’s perianal fistulas. Clinical remission was observed in 65% of participants, with a clinical response rate of 73% for the All Treated group. The study has enrolled 230 patients as of September 2021. While adverse events were noted in 20% of participants, no serious incidents such as deaths or ectopic tissue formation were reported. These findings align with previous Phase 3 study results, supporting Alofisel's potential as a viable treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.